CEL-SCI
Innovative immunotherapy solutions for cancer, autoimmune, and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $5.7m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1970 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (2213 %) | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 1266 % | - | - | - | - | - |
Source: Company filings or news article
Related Content
CEL-SCI Corporation, founded in 1983 and listed on NYSE American under the ticker CVM, is a biotechnology company focused on the research and development of immunotherapy products. The company aims to improve the treatment of cancer, autoimmune, and infectious diseases by leveraging the body's natural defense system, the immune system. CEL-SCI's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is being developed to enable the immune system to mount an anti-tumor response with minimal toxicity to normal cells and organs. CEL-SCI operates in the biotechnology sector, primarily serving patients diagnosed with cancer and other severe diseases. The company generates revenue through the development and potential commercialization of its proprietary therapies.
Keywords: immunotherapy, cancer treatment, autoimmune diseases, infectious diseases, drug discovery, biological substances, Multikine, biotechnology, immune system, clinical trials.